A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Inclusion Criteria:

• Be willing and able to understand the study procedures and the risks involved andprovide written informed consent before the first study-related activity

• Be male or female ≥18 years of age.

• Have type 1 or type 2 diabetes mellitus and a HbA1c of ≤12%.

• Have a decrease in vision in the study eye determined by the investigator to beprimarily the result of DME.

Exclusion Criteria:

• Be pregnant or breastfeeding

• History of cataract surgery and/or minimally invasive glaucoma surgery in the studyeye within 90 days of Screening

• Have any treatment for complications of cataract surgery with steroids or yttriumaluminum garnet (YAG) laser capsulotomy within 90 days of Screening

• Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine,pentosan polysulfate sodium, and amiodarone)

• If treatment-experienced for DME have a history of any of the following treatmentswithin the noted time windows:

• Have had prior treatment with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye

• Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab,aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90days of the Screening visit